Oracle and AstraZeneca Plan AI Clinical-Trial Partnership

Oracle and AstraZeneca say they will explore using AI and real-world health data to help identify patients for clinical trials and bring research insights into care. The non-binding agreement covers potential projects in cancer, cardiovascular, kidney and metabolic diseases, respiratory and immune conditions, and rare diseases. ^[1][2]

AstraZeneca says the first program will focus on hypertension care and clinical research in Abu Dhabi, with healthcare company M42. The companies say they intend to use de-identified data under privacy and governance safeguards; AstraZeneca says it will not receive patient-identifiable information. ^[1]

The announcement describes planned areas of exploration, not demonstrated improvements in trial recruitment, safety monitoring or patient outcomes. Each proposed project will require separate legal, privacy, regulatory, ethical and institutional review before proceeding, according to AstraZeneca. ^[1]